Replies to post #3019 on Ayala Pharmaceuticals Inc (ADXS)

[fbg0316]

The proposed OIP increase is not just excessive, it is insulting to shareholders considering the +50% drop in the value of the stock over the last couple years, coupled with the fact ADXS removed the OIP from last year's proxy claiming they did so because they believed it was important to align management interests with those of shareholders.